Generate a quick AI overview of this bid, pulled from its details and the attached documents.
PRE SOLICITATION NOTICE
Department of Veterans Affairs Network Contracting Office (NCO) 05
Title: A Joint Targeted Drug Delivery Approach for Arthritis Therapy Toxicity and Pharmacokinetics
The Department of Veterans Affairs (VA), Network Contracting Office (NCO) 05, intends to issue a solicitation for preclinical toxicology and pharmacokinetic (PK) studies to support advancement of an experimental joint targeted liposomal delivery system for Rheumatoid Arthritis therapy. This requirement involves GLP compliant toxicity studies and GLP or non GLP PK studies in adult rats.
The forthcoming solicitation will seek a contractor capable of performing:
GLP single dose IV toxicity studies including clinical observations, weight/food intake monitoring, blood chemistry assessments, necropsy, and histopathology.
GLP or non GLP pharmacokinetic studies including IV dosing, timed blood collection, plasma processing and storage, LC MS/MS analysis of dexamethasone and 6 hydroxydexamethasone, and calculation of PK parameters.
A comprehensive final written report covering toxicity results, PK data, and analytical findings.
Place of performance will be the contractor s laboratory. The anticipated period of performance is one year, approximately September 15, 2026 through September 14, 2027.
This notice is issued solely for informational purposes. A formal solicitation and the Government s acquisition strategy will be issued after completion of market research.
This notice does not constitute a solicitation and does not commit the Government to award a contract.
Point of Contact:
Robert O Keefe Jr., Contract Specialist
Email: robert.okeefejr@va.gov
Source: SAM.gov (notice 750f005515244b6eb709587fd0f1a412), retrieved via the SAM.gov Get Opportunities API. View the official posting — always confirm requirements and deadlines with the issuing agency.
Here are some similar opportunities
Let our AI help you find the right opportunity
Search with AI →